Inovio Pharmaceuticals(INO) - 2023 Q1 - Earnings Call Transcript
Inovio Pharmaceuticals(INO)2023-05-11 07:34
Next, I'd like to share some highlights on the cellular and immune response we saw in this trial. Treatment induced cellular responses against both HPV-6 and HPV-11, inducing both activated CD4 and activated lytic CD8 T-cells. We believe this type of cytotoxic CD8 T-cell response may be important in clearing HPV infected cells. T-cell responses were also observed at week-52, which was 43 weeks after final treatment with INO-3107 indicating a persistent cellular memory response. Additional analyses are also ...